-
CD ROM
-
Hard Copy
-
Electronic (PDF)
-
Enterprisewide
Advanced Lung Cancer in Patient Light Smoker with Lung Adenocarcinoma
The Assessment Group, April 2011, Pages: 28
A patient specific case scenario on advanced lung cancer in a situation involving a patient that is a light smoker with lung adenocarcinoma that progresses throughout the report, presented to 158 high-prescribing oncologists for their open responses on clinical decisions.
Patient progression reveals:
- Decisions in treatment and tests through disease stages
- Factors influencing their decisions
- Barriers to optimal patient care
- Confidence in treatment
Data has been synthesized to show all responses and direct quotes from the oncologists. This is the primary research for the oncology prescribing data that you are missing - directly from high-prescribing US oncologists on Advanced Lung Cancer.
Treatment decisions for advanced stages of lung cancer are difficult to track as information quickly changes along with the introduction of new products that all have an impact oncologists' choices. This report is part of a series of oncology reports that allow you to see what is actually happening at the patient level for different types of patients presenting with a wide range of issues in advanced stages of cancer.
This report allows you to:
- Understand what occurs with actual patients
- Access the most up-to-date prescribing trends
- Gain actionable data for developing and improving your market strategies
- Pinpoint needs of your target audience
- Focus resources to maximize the effectiveness of your budget
- Understand where your product fits
- Understand where your competitor's product fits
- Design messages to advance brand performance
Executive Summary
Chapter 1: Introduction
Table 1: Treatment Options in Advanced Lung Cancer
Chapter 2: Respondent Demographics
Table 2: Eligibility Criteria for Survey Participation
Figure 2.1 Gender of Survey Respondents
Figure 2.2 Years Since Medical School Graduation
Figure 2.3 Practice Settings
Figure 2.4 Practices in NCI Cancer Centers
Figure 2.5 Geographic Settings
Figure 2.6 Survey Respondents by State's Lung Cancer Mortality
Figure 2.7 Number of Physicians in Practice Groups
Figure 2.8 Minimal Acceptable Level of Evidence in Determining Treatment Regimen
Chapter 3: Treatment of an EGFR Mutation Positive Adenocarcinoma
Figure 3.1 First line chemotherapy regimen
Figure 3.2 Factors influencing treatment decision
Figure 3.3 Confidence in treating patient to an optimal outcome
Figure 3.4 Sequence of treatment choices
Figure 3.5 Factors influencing treatment decision
Figure 3.6 Barriers to management of advanced lung cancer
Chapter 4: Summary
Appendix A: Survey Instrument
- Eli Lilly
- Genentech/Roche
- Bristol-Myers Squibb
- Glaxo Smith Kline
- Pfizer
- Sanofi-aventis
Products mentioned:
- Alimta
- Avastin
- Erbitux
- Exelbine
- Taxol
- Gemzar
- Paraplatin
- Platinol
- Tarceva
- Taxotere
Product Samples
A sample for this product is available. Please Login/Register to download this sample.
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
